Consultant Deloitte, New York, announced it has reached an agreement to buy data-miner Recombinant Capital, Walnut Creek, Calif., whose databases including information about business alliances, intellectual property ownership and clinical trials data in the biotechnology and pharmaceutical industries, the consultant announced.
Terms of the deal were not disclosed. The transaction should be completed by next month, the company said.
According to a news release, Recombinant Capital offers a subscription database service to 1,500 subscribers that contains more than 20 years of historical information. Its customers include 90% of the largest pharmaceutical and biotech companies, as well as medical centers, universities, law and venture capital firms. A statement on its Web site said that Recombinant Capital provides answers to real-world business questions surrounding clinical drug development including complete coverage of biotech clinical trials, with indication timelines, individual trial details, supporting regulatory documents (and) abstracts.
Deloitte will use the data in its life sciences consulting practice as well as in other aspects of its business, according to the company.